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Case RepoRt
Whether or not patients whose red blood cells (RBCs) carry 
certain weak D types  produce anti-D, and if they do whether it is 
allo- or autoanti-D, remains controversial. The aim of this study 
was to determine the serologic features of anti-D in individuals 
expressing a weak D other than type 1 or type 2 and to assess 
whether the anti-D was an allo- or autoantibody. Serologic D 
typing and molecular analyses were performed on 748 individuals. 
Serologic characterization of anti-D included autologous controls, 
direct antiglobulin test, elution, and titration of anti-D before and 
after adsorption of serum onto autologous RBCs. From molecular 
analyses, 459 individuals exhibited a weak D type. We described 
seven novel RHD variant alleles. The most frequent types of weak 
D were type 1 (30.1%), type 2 (23.7%), type 4.0 (10.2%), type 4.2.2 
(20.3%), type 11 (3.9%), and type 15 (3.7%). Anti-D was identified 
in the sera of 9 of 47 individuals with weak D type 4.0, in 14 of 
93 with weak D type 4.2.2, in 1 of 18 with weak D type 11, in 1 
of 17 with weak D type 15, and in 1 weak D type 33 individual. 
Anti-D was demonstrated to be an alloantibody in weak D type 
4.0, type 4.2.2, and type 15 individuals, but an autoantibody 
in weak D type 11 and type 33 individuals. In conclusion, only 
a complete serologic investigation of individuals with a given 
weak D type identified by molecular analysis allows concluding 
on the nature of the antibody. Transfusing weak D type 4.2.2 
and type 15 patients with D– RBC units and proposing anti-D 
immunoprophylaxis to women with these weak D types should be 
considered. Immunohematology 2013;29:55–62.
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molecular analysis
The D (RH1) antigen is of clinical importance with 
regard to hemolytic disease of the fetus and newborn (HDFN) 
and transfusion medicine.1 This antigen is still the leading 
cause of HDFN. Furthermore, anti-D has the potential to 
cause severe hemolytic transfusion reactions. The D antigen 
carried by the RhD protein is the most immunogenic of the 
Rh antigens. It has been described as a mosaic composed of 
multiple epitopes thought to be highly conformational.2,3 The 
high immunogenicity of the D antigen is related to the fact 
that the entire RhD protein is absent from the red blood cell 
(RBC) membrane of individuals expressing a D– phenotype. 
Issitt and Anstee reported that approximately 80 percent of 
D– healthy volunteers transfused with one or more D+ blood 
units produce anti-D.4 However, more recent data show that 
only 20 to 30 percent of D– patients transfused with one or 
more D+ units produce anti-D.5–7
The RhD protein is exclusively expressed on RBCs. From 
structural models, this protein has been predicted to consist 
of 12 transmembranous helixes with six extracellular regions. 
The Rh proteins are encoded by two homologous genes, 
RHD and RHCE. RHD encodes the RhD protein, whereas 
RHCE encodes the RhCE protein, carrying the C/c and E/e 
polymorphisms. Each gene consists of ten exons. The opposite 
orientation of the RHD and RHCE genes on chromosome 
1 favors great diversity of these genes as a result of genomic 
rearrangements.8 A large number of RHD alleles that result 
in D variants have been identified. The term D variant refers 
to RhD proteins associated with a quantitative or qualitative 
change of D expression. Classically, weak D, related to a 
quantitative change of D expression, has been defined as 
RBCs giving a weaker reaction than RBCs of the same Rh 
phenotype as reference, according to a defined anti-D reagent 
and a defined technique. Weak D differs from partial D, as the 
latter is associated with a qualitative change of D expression. 
This difference is of clinical importance because patients with 
a partial D phenotype have the potential to produce alloanti-D 
against the part of D they lack. More recently, D variants have 
been classified at the molecular level. Based on RHD sequence 
variations, genetic variants changing the amino acid sequence 
predicted to be in the membrane-spanning or intracellular 
regions of the RhD protein were considered to be a feature of 
weak D, whereas genetic variants changing the amino acid 
sequence predicted to be in the extracellular regions were 
considered to be a feature of partial D.9 Until now, assignment 
of variant D type resulting from molecular analysis has 
reported more than 70 different weak D types.10
The weak D phenotype has been a subject of controversy 
since it was described in 1946.11 Stratton first described RBCs 
reacting in an atypical manner with anti-D, introducing the 
term “DU” phenotype corresponding to a weakened form of 
D. Considering the evolution of the anti-D reagents (mostly 
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monoclonal antibodies or MoAbs) and techniques over the 
years, no definitive serologic variation has been established 
in the majority of weak D types. For some time, it was 
generally accepted that patients with a weak D phenotype 
express a weak but normal entire D antigen.8 Consequently, 
the possibility of D immunization related to weak D types was 
disregarded by many. However, some authors showed that 
patients with weak D phenotype may produce alloanti-D,12–14 
suggesting that most weak D types carry altered D antigen.12 
Recently, by performing a complete serologic investigation, we 
demonstrated that anti-D in weak D type 1 or weak D type 2 
individuals were autoantibodies.15 The aim of the present study 
was to determine the serologic features of anti-D in individuals 
expressing a weak D type, excluding type 1 or type 2, and to 
assess the clinically relevant potential for anti-D immunization 
in individuals with some weak D types.
Materials and Methods
Samples
Samples were obtained from 748 individuals referred to 
the Centre National de Référence pour les Groupes Sanguins 
(CNRGS) between 2007 and 2010 for different reasons, 
namely, depressed D phenotype, discordant results between 
two anti-D reagents, or anti-D in individuals with a D+ 
phenotype. EDTA blood (15 mL) and serum (15 mL) were 
obtained from these individuals for serologic D typing and 
molecular RHD testing.
Serology
D antigen status, together with C, E, c, and e status, was 
evaluated using two commercially available reagents: one 
monoclonal reagent (Ortho BioVue System, Ortho Clinical 
Diagnostics, Raritan, NJ), and one polyclonal reagent (DiaMed, 
Cressier/Morat, Switzerland), with gel testing according to the 
manufacturers’ recommendations. These reagents are “CE 
marked,” and they are licensed according to the European 
Community Standards.
D antigen reactivity was further analyzed using 
immunoglobulin (Ig) G MoAbs and an IgM MoAb. The IgG 
MoAbs were HIRO3 and HIRO7 from the Japanese Red Cross 
(Dr. Uchikawa), D7 from Dr. Sondag-Thüll (Liège, Belgium), 
415-1E4 from Dominion Biologicals Ltd. (Dartmouth, 
Canada), P3x249, P3x35, and HM16 from Diagast (Loos, 
France), FEF3 from the International Blood Group Reference 
Laboratory, United Kingdom (Dr. Anstee), and RD7C2 from 
Institut Pasteur de Paris, France (Dr. Edelman). The IgM 
MoAb was P3BROU7 from Etablissement Français du Sang, 
Rennes, France (Dr. Martin).
The direct antiglobulin test (DAT) using gel method 
(anti-IgG and anti-C3d separately) was performed using the 
commercial kit DC-Screening II (DiaMed), according to the 
manufacturer’s recommendations.
Elution was performed on the RBCs of individuals 
producing anti-D using an acid elution method (Gamma Elu-
Kit II, Immucor Gamma, Norcross, GA). The kit was used 
according to the manufacturer’s recommendations. The eluate 
was tested using an indirect antiglobulin test (IAT) gel method 
(DiaMed), according to the manufacturer’s recommendations, 
with native and papain-treated RBCs.
Anti-D was identified by testing the serum against a panel 
of RBCs (Reference National Panel, Paris, France). The IAT 
gel method was performed according to the manufacturer’s 
instructions (DiaMed), with native and papain-treated RBCs.
Adsorption with autologous RBCs was performed when 
samples were obtained in sufficient quantity and if there was 
no history of transfusion in the past 4 months. Adsorption 
of serum onto an equal volume of washed papain-treated 
autologous RBCs was performed at 37°C for 40 minutes, 
followed by centrifugation at 3100g for 10 minutes. The serum 
was adsorbed a minimum of three times. The remaining 
serum was tested against papain-treated RBCs in an IAT gel 
test.
Anti-D was titrated against a pool of papain-treated D+C–
E+c+e– RBCs by using IAT at 37°C. The titration end point 
of anti-D was determined before and after adsorptions onto 
autologous RBCs.
Molecular Testing
Genomic DNA was extracted from whole-blood samples 
by using the MagNA Pure Compact Instrument (Roche 
Molecular Biochemicals, Mannheim, Germany) with the 
MagNA Pure Compact Nucleic Acid Isolation Kit I (Roche 
Molecular Biochemicals), according to the manufacturer’s 
recommendations.
Allele-Specific polymerASe chAin reActionS
RHD allele-specific primer amplification assays, primer 
sequences, and polymerase chain reaction (PCR) conditions 
to detect the RHD*weak D type 1 (RHD*01W.1) and the 
RHD*weak D type 2 (RHD*01W.2) alleles were previously 
described.16
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exon AmplificAtion for DnA Sequence AnAlySiS
PCR exon amplification was performed on genomic DNA 
for sequence analysis. RHD primer sequences were previously 
described.17,18 The ten RHD exon PCRs were performed in a 
thermal cycler on 100 ng of genomic DNA in a total reaction 
volume of 50 µL. Reaction mixtures contained 10 µM of each 
primer, 200 µM of each deoxyribonucleoside triphosphate 
(Amersham Biosciences, Piscataway, NJ), and 2.5 U of Taq 
DNA polymerase (Gold, Applied Biosystems, Carlsbad, CA) 
or 1 µL of Taq DNA polymerase for exon 5 (Advantage 2 
polymerase mix, Clontech Laboratories, Mountain View, CA) 
in the appropriate buffer.
PCR products were purified (Exosap-it, Affymetrix UK 
Ltd., High Wycombe, UK), and cycle sequenced by using 
BigDye terminator chemistry (ABI-PRISM BigDye Terminator 
v1.1 Cycle Sequencing Kits, Applied Biosystems). Sequences 




From the 748 individuals systematically tested using 
molecular RHD analysis, a total of 459 individuals (61.3%) 
exhibited a D variant that could be named weak D according 
to the RhesusBase classification.10 The different weak D 
types found in this study and their prevalence are reported 
in Table 1. The RHD allele characterized by the 602C>G, 
667T>G, 744C>T, 957G>A, and 1025T>C polymorphisms in 
RHD exons 4, 5, and 7 was named RHD*weak D type 4.2.2 
according to its first molecular description.12,19 This RHD allele 
may be dubbed DAR, an allele which shares the 602C>G, 
667T>G, and 1025T>C nucleotide polymorphisms found in 
weak D type 4.2.2 but lacks the silent 744C>T and 957G>A 
polymorphisms.20 Weak D type 4.2.2 is currently listed as a 
“partial D” on the RhesusBase; International Society of Blood 
Transfusion (ISBT) allele terminology describes this allele 
as carrying the 602C>G, 667T>G, 744C>T, and 1025T>C 
polymorphisms. We described seven novel variant RHD alleles 
(Table 1). The N1, N2, N3, N4, N5, N6, and N7 novel variant 
alleles were derived from a DCe (R1), DCe, DcE (R2), Dce (R0), 
DcE, DCe, and DCe haplotype, respectively.
Of the 748 individuals, 138 (18.5%) exhibited a partial D. 
As the focus of this study is weak D types, no further analysis 
or discussion of these samples is included here. Genomic DNA 
sequencing of all exons in 65 cases (8.7%) did not identify 
known variant RHD alleles. No exonic variants were found 
in most cases. cDNA analysis would be necessary to rule out 
other variants; these samples were not pursued further. An 
additional 86 samples (11.5%) were not pursued further; these 
included samples with two variant RHD alleles or incomplete 
or pending analysis.
Serologic Data
Anti-D was identified in 7 weak D type 1 individuals 
(5.1%), 6 weak D type 2 individuals (5.5%), 9 weak D type 
4.0 individuals (19.1%), 14 weak D type 4.2.2 individuals 
(15.1%), 1 weak D type 11 individual (5.5%), 1 weak D type 15 
individual (5.9%), and 1 weak D type 33 individual (Table 1).
WeAk D type 4.0
All 47 individuals expressing a weak D type 4.0 exhibited 
a D+C–E–c+e+ phenotype. The reactivity of weak D type 4.0 
RBCs with selected D MoAbs is detailed in Table 2.
When using the panel of anti-D MoAbs, the strength of 
the positive reaction obtained varied when using IgG MoAbs; 
RD7C2 gave a negative reaction (data not shown).
Anti-D was detected in 9 of the 47 individuals (19.1%) 
exhibiting a weak D type 4.0. Serologic data from five cases 
(C-1 to C-5) are reported in Table 3. Transfusion history and 
pregnancies related to these individuals are listed in Table 3. No 
data were reported for the four other cases as a result of recent 
transfusion. To sum up, anti-D was demonstrated to be an 
alloantibody in one case (C-1). In this case, the anti-D reactivity 
was not significantly reduced after autologous adsorptions. 
Autologous controls, DAT, and eluate were negative. In 
contrast, anti-D was demonstrated to be an autoantibody in 
two other cases (C-4 and C-5). In these cases, the titer and 
score were significantly reduced (at least 2 dilutions for the 
titer and 16 for the score) after autologous adsorptions. In C-4, 
the autologous controls and the DAT were positive, and anti-D 
was present in the eluate. In C-5, autologous controls and 
DAT were negative. Finally, no conclusion about the nature 
(alloantibody or autoantibody) of anti-D could be reached from 
the incomplete serologic data in the last two cases (C-2 and 
C-3). No alloantibody against other antigens of blood group 
systems was detected in C-1 to C-5.
WeAk D type 4.2.2
All of the 93 individuals expressing a weak D type 4.2.2 
exhibited a D+C–E–c+e+ phenotype. The reactivity of weak D 
type 4.2.2 RBCs with selected D MoAbs is detailed in Table 2.
When using the panel of anti-D MoAbs, the strength of 
reaction obtained varied when using HIRO3, HIRO7, D7, 415-
1E4, P3x249, P3x35, and HM16 IgG MoAbs (data not shown).
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Anti-D was detected in 14 of the 93 individuals (15.1%) 
exhibiting a weak D type 4.2.2. Notably, it was found in 
combination with anti-Hr (RH18) in 8 of the 14 patients (C-
12 to C-19). Serologic data related to anti-D investigation are 
reported in Table 4. Transfusion history and pregnancies 
related to these individuals are listed in Table 4. To sum up, 
anti-D was demonstrated to be an alloantibody in two cases 
(C-6 and C-7). After autologous adsorptions, the anti-D 
reactivity was not significantly reduced. Autologous controls, 
DAT, and eluate were negative. In the other 12 cases, no 
conclusion about the nature (allo- or autoantibody) of anti-D 
could be made from the incomplete serologic data.
WeAk D type 11
All 18 individuals expressing a weak D type 11 exhibited 
a D+C+E–c+e+ phenotype. Our results were concordant with 
previous studies reporting that the weak D type 11 was a weak 
form of D named DEL (Del) when encoded by a DCe haplotype 
in the Caucasian population.21
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Table 1. Weak D type and antibody status in individuals exhibiting a weak D phenotype identified in this study
Trivial names* Molecular changes carried by the corresponding RHD allele N
% of the total 
weak Ds
Number of individuals 
with anti-D (%)
Weak D type 1 809T>G (RHD*01W.1) 138 30.1% 7 (5.1%)
Weak D type 2 1154G>C (RHD*01W.2) 109 23.7% 6 (5.5%)
Weak D type 3 8C>G (RHD*01W.3) 6 1.3% 0
Weak D type 4.0 602C>G, 667T>G, 819G>A (RHD*weak partial 4.0) 47 10.2% 9 (19.1%)
Weak D type 4.2.2 602C>G, 667T>G, 744C>T, 957G>A, 1025T>C† (RHD*weak 4.2.2) 93 20.3% 14 (15.1%)
Weak D type 4.2.3 602C>G, 667T>G, 744C>T, 1025T>C 7 1.5% 0
Weak D type 5 446C>A (RHD*01W.5) 1 NA 0
Weak D type 10 1177T>C (RHD*01W.10) 2 NA 0
Weak D type 11 885G>T (RHD*weak partial 11) 18 3.9% 1 (5.5%)
Weak D type 15 845G>A (RHD*weak partial 15) 17 3.7% 1 (5.9%)
Weak D type 17 340C>T (RHD*01W.17) 1 NA 0
Weak D type 18 19C>T (RHD*01W.18) 4 NA 0
Weak D type 20 1250T>C (RHD*01W.20) 1 NA 0
Weak D type 27 661C>T (RHD*01W.27) 2 NA 0
Weak D type 33 520G>A (RHD*01W.33) 1 NA 1
Weak D type 38 833G>A (RHD*01W.38) 1 NA 0
Weak D type 56 65C>A (RHD*01W.56) 3 NA 0
Weak D type 59 1148T>C (RHD*01W.59) 1 NA 0
Novel weak D = N1 208C>T, 818C>T, 1195G>A 1 NA 0
Novel weak D = N2 542T>C 1 NA 0
Novel weak D = N3 730G>C 1 NA 0
Novel weak D = N4 731C>T 1 NA 0
Novel weak D = N5 751A>C 1 NA 0
Novel weak D = N6 884T>C 1 NA 0
Novel weak D = N7 1107A>C 1 NA 0
Total = 459 Total = 39 (8.5%)
* Trivial names assigned by RhesusBase.10
† The RHD allele was named RHD*weak D type 4.2.2 according to its first molecular description.12 This RHD allele may be dubbed DAR, the sequence of which 
shares the 602C>G, 667T>G, and 1025T>C polymorphisms found in RHD*weak D type 4.2.2 but lacks the silent 744C>T and 957G>A polymorphisms.20
NA = not applicable.
Table 2. Reaction strengths of samples with weak D type 4.0 and 
weak D type 4.2.2 in tests with MoAb anti-D










4+ 25 4 20 3
3+ 19 27 58 11
2+ 1 14 12 44
1+ 0 1 3 17
Negative 2 1 0 18
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When using the panel of anti-D MoAbs, a very weak 
positive reaction was obtained with the HIRO3, D7, and 
P3x249 MoAbs only (data not shown).
Anti-D was detected in 1 of the 18 individuals (5.5%) 
exhibiting a weak D type 11. This patient produced an 
autoanti-D (Table 5, C-20). The anti-D reactivity (titer of 32, 
and score of 53 before autologous adsorptions) was not detected 
after autologous adsorptions. Autologous controls, DAT, and 
eluate were negative. No alloantibody against antigens of other 
blood group systems was detected.
WeAk D type 15
Among the 17 individuals expressing a weak D type 
15, 9 exhibited the D+C–E+c+e+ phenotype described by 
Wagner et al.9 However, 8 individuals exhibited a D+C+E–
c+e+ phenotype. When using monoclonal anti-D or polyclonal 
anti-D, a negative reaction was observed for all samples.
When using the panel of anti-D MoAbs, a weak positive 
reaction was obtained with HIRO3, HIRO7, D7, and 415-1E4 
IgG MoAbs (data not shown).
Alloanti-D was detected in 1 of the 17 individuals (5.9%) 
exhibiting a weak D type 15 (Table 5, C-21). After autologous 
adsorptions, anti-D was present, without significant reduction 
of either the titer or the score (1 dilution for the titer, and 10 for 
the score). Autologous controls, DAT, and eluate were negative. 
No alloantibody against antigens of other blood group systems 
was detected.
Table 3. Serologic data of anti-D in weak D type 4.0 individuals


























C-1 Female Yes Unk Negative Positive Negative Negative Negative Negative 8/31 4/23 5
C-2 Female Unk Yes Positive Positive Negative Negative Negative Negative 128/55 NT NA
C-3 Female Yes Unk Negative Positive Negative Negative Negative Negative NT NT NA
C-4 Female Yes Yes Positive Positive Positive Positive Positive (IgG) Anti-D 16/44 1/5 5
C-5 Female Yes Unk Positive Positive Negative Negative Negative NT 8/35 1/2 4
*Anti-D tested and titrated against papain-treated RBCs (gel-test).
RBCs = red blood cells; DAT = direct antiglobulin test; Unk = unknown; NT = not tested; NA = not applicable; IgG = immunoglobulin G.
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Table 4. Serologic data of anti-D in weak D type 4.2.2 individuals


























C-6 Female Unk Yes Negative Positive Negative Negative Negative Negative 8/35 4/23 4
C-7 Female No Yes Positive Positive Negative Negative Negative NT 16/40 8/25 3
C-8 Female Unk Yes Positive Positive Negative Negative Negative Negative 2/13 NT NA
C-9 Female Unk Yes Positive Positive Negative Negative Negative Negative NT NT NA
C-10 Male Yes NA Positive Positive Negative Negative Negative NT NT NT NA
C-11 Male Yes NA Negative Positive Positive Positive Negative NT NT NT NA
C-12 Female Unk Yes Negative Positive Negative Negative Negative NT NT NT NA
C-13 Female Unk Yes Negative Positive Negative Negative Negative NT NT NT NA
C-14 Female Yes Yes Negative Positive Negative Negative Negative NT NT NT NA
C-15 Female No Yes Negative Positive Negative Negative Negative NT NT NT NA
C-16 Female No Yes Negative Positive Negative Negative Negative NT NT NT NA
C-17 Female No Yes Positive Positive Negative Negative Negative NT NT NT NA
C-18 Female No Yes Positive Positive Negative Negative Negative NT NT NT NA
C-19 Female Yes Yes Negative Positive Negative Negative Negative NT NT NT NA
*Anti-D tested and titrated against papain-treated RBCs (gel-test).
RBCs = red blood cells; DAT = direct antiglobulin test; Unk = unknown; NT = not tested; NA = not applicable.
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WeAk D type 33
Only one D+C+E–c+e+ individual was found to express a 
weak D type 33. When using monoclonal anti-D or polyclonal 
anti-D, a negative reaction was observed when testing the 
blood sample from the weak D type 33 individual.
When using the panel of anti-D MoAbs, a positive reaction 
was obtained when using the P3BROU7 IgM MoAb and all 
IgG MoAbs except RD7C2.
This weak D type 33 patient produced an autoanti-D 
(Table 5, C-22). The anti-D reactivity was not detected after 
autologous adsorptions. Autologous controls were positive. 
Anti-D was present in the eluate despite a negative DAT. No 
alloantibody against antigens of other blood group systems 
was detected.
Discussion
From our experience, molecular RHD analysis appears 
to be the only reliable method to identify D variants. The D 
antigen expression of a given D variant appears variable when 
tested serologically. Our previous study clearly showed the 
variable reactivity with anti-D of RBCs expressing weak D 
type 1 and that of RBCs expressing weak D type 2.15 In the 
same way, the present study clearly showed that the reactivity 
of RBCs expressing weak D type 4.0 or weak D type 4.2.2 
ranged from 4+ to 0, despite using a defined validated method 
with a CE-marked anti-D monoclonal or polyclonal reagent. 
These data reinforce our feeling that the identification of a D 
variant should never be based on serologic criteria owing to 
its variable expression. Consequently, our recommendation 
would be to perform molecular RHD analysis when D 
expression is weakened when compared with normal D 
expression, whatever the level of decreased reactivity, or if 
anti-D is produced by a D+ individual.
Molecular testing has allowed identification of more than 
150 different D variants. Based on RHD sequence variation, the 
widely used classification found on RhesusBase has assigned 
names to D variants, weak D or partial D, referenced in the 
ISBT allele terminology.10,19 In our study, the most frequent 
weak D types were weak D type 1, type 2, type 4.0, type 4.2.2, 
type 11, and type 15. When available, it is useful to give RH 
haplotype information when describing a novel RHD allele. In 
accordance with data listed on RhesusBase, weak D type 1, 
type 2, type 4.0, and type 4.2.2 were found to be encoded by 
DCe, DcE, Dce, and Dce haplotypes respectively. Weak D type 
11 was found to be encoded by a DCe haplotype, as expected 
when expression of this D variant corresponds to a “DEL 
phenotype.”21 Interestingly, our study first reports that weak D 
type 15 may be encoded either by the expected DcE haplotype 
or by a DCe haplotype. Whether the presence of C in cis affects 
the D antigen density requires further study. In our laboratory, 
the frequencies of weak D type 1, type 2, type 4.0, type 4.2.2, 
type 11, and type 15 were 30.1, 23.7, 10.2, 20.3, 3.9, and 3.7 
percent, respectively, for the 459 weak D types identified 
using molecular methods. These particular frequencies are 
likely biased because of our recruitment strategy toward a 
population of African ancestry. Actually, weak D type 1, weak 
D type 2, and weak D type 3 have been reported to be the 
most prevalent D variants found in the white population.22–26 
In contrast, weak D type 4.0 and weak D type 4.2.2 have been 
reported to be mostly found in the African population.10 Thus, 
our results are in accordance with the D variant frequencies 
expected when a mixed population is tested.27–29
Whether patients carrying certain molecular weak D 
types are prone to anti-D immunization has been questioned 
for many years and followed through a Rhesus immunization 
registry.10 After our recent study about anti-D immunization in 
weak D type 1 or type 2 individuals,15 we perform a complete 
serologic investigation whenever possible in individuals 
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Table 5. Serologic data of anti-D in weak D type 11, 15, or 33 individuals




























C-20 Female Yes Unk Weak D 
type 11
Negative Positive Negative Negative Negative NT 32/53 Neg† 4
C-21 Female No Yes Weak D 
type 15
Negative Positive Negative Negative Negative Negative 64/69 32/62 4
C-22 Female Yes Unk Weak D 
type 33
Negative Positive Positive Positive Negative Anti-D 4/20 Neg 5
*Anti-D tested and titrated against papain-treated RBCs (gel-test).
†Neg indicates titer = 0/score = 0.
RBCs = red blood cells; DAT = direct antiglobulin test; Unk = unknown; NT = not tested.
IMMUNOHEMATOLOGY, Volume 29, Number 2, 2013 61
expressing a weak D type other than type 1 or type 2. The 
serologic investigation includes autologous controls, DAT, 
elution, and titration of anti-D before and after adsorption of 
serum onto autologous RBCs. In our experience, titration of 
anti-D before and after adsorption of serum onto autologous 
RBCs is the most informative test, indicating the nature (allo- 
or auto-) of the antibody. In this study, anti-D was identified 
in 19.1 percent of weak D type 4.0 individuals, 15.1 percent of 
weak D type 4.2.2 individuals, 5.5 percent of weak D type 11 
individuals, 5.9 percent of weak D type 15 individuals, and 1 
weak D type 33 individual.
In weak D type 4.0 individuals, a complete serologic 
analysis was performed in three cases. Interestingly, the 
serologic data demonstrated that anti-D was an alloantibody 
in one case (C-1), but an autoantibody in the other two cases 
(C-4 and C-5). To our knowledge, only two cases of weak D 
type 4.0 individuals developing anti-D have been reported 
in the Rhesus immunization registry to date. Yet, the allo- or 
autoantibody nature of anti-D has not been determined. Based 
on a complete serologic investigation in C-1, we conclude 
that weak D type 4.0 individuals may produce alloanti-D. 
The presence of autoanti-D in weak D type 4.0 individuals 
may not weaken the case for our hypothesis because it may 
be attributable to an autoimmune reaction unrelated to the 
expression of this weak D type. However, other complete 
documented cases are required to definitively conclude this.
In weak D type 4.2.2 individuals, this report showed these 
anti-D to be alloantibodies. This conclusion is in accordance 
with the incomplete serologic data reported in previous 
studies.12,20 In the only weak D type 11 individual producing 
anti-D, the serologic investigation allowed us to conclude that it 
was an autoantibody. The discordance between our result and 
the one listed in the Rhesus immunization registry reporting 
an alloanti-D without serologic data reinforces our hypothesis 
that discussions about anti-D in weak D patients should 
systematically be based on the four different tests discussed 
previously to determine whether anti-D is an allo- or an 
autoantibody. In the only weak D type 15 individual producing 
anti-D, data obtained with a complete serologic investigation 
demonstrated that the anti-D was an alloantibody. This result 
was in accordance with the data reported by Wagner et al.12 
Finally, in the only weak D type 33 individual producing 
anti-D, the latter was demonstrated to be an autoantibody.
The documentation of anti-D (auto- or alloantibody) 
is a major issue for weak D individuals.30 Consequences are 
recommendations provided for transfusion strategy and 
to pregnant women regarding the frequency of the weak D 
types. The first concern is that anti-D production may only be 
studied in individuals expressing a D variant whose frequency 
is high enough for it to be spotted. The second concern is that 
only complete serologic investigation should be taken into 
account. Therefore, the demonstration of only autoanti-D in 
individuals expressing a given weak D type should lead to 
transfusing patients expressing the same weak D type with 
D+ RBC units and not giving anti-D immunoprophylaxis 
to pregnant women. So our recommendation is to transfuse 
weak D type 1 and type 2 patients with D+ RBC units and 
not give anti-D immunoprophylaxis to pregnant women of 
these types.15 On the other hand, the demonstration of an 
alloanti-D immunization in an individual expressing a given 
weak D may lead to transfusing patients expressing the same 
weak D type with D– RBC units, and to proposing anti-D 
immunoprophylaxis to pregnant women of these types. 
Therefore, transfusing weak D type 4.2.2 and type 15 patients 
with D– RBC units and proposing anti-D immunoprophylaxis 
to pregnant women should be considered. Considering weak D 
type 4.0, we recommend the D– transfusion policy and anti-D 
immunoprophylaxis in our laboratory. However, other cases 
should be documented at the international level.
Finally, the lack of anti-D immunization is not a 
prerequisite for labeling a weak D type.14 However, the notion 
of anti-D immunization should be taken into account. The 
present study clearly confirms that the RBCs of individuals 
with some weak D types carry altered D antigens, as 
alloanti-D was shown to be produced by patients expressing 
a D variant associated with RHD genetic variants encoding 
amino acid substitutions in the membrane-spanning or the 
cytoplasmic domain of the D protein, contrary to the concept 
that alloanti-D may be produced by patients expressing a D 
variant associated with RHD polymorphisms encoding amino 
acid substitutions in the extracellular loops of the D protein. 
These data point out that the discrimination between weak D 
types and partial D may be a “delicate affair” as the serologic 
definition, the predicted location of amino acid polymorphisms 
deduced from molecular sequences, or the notion of anti-D 
immunization may be flawed. Consequently, to make accurate 
clinical decisions in terms of transfusion policy and anti-D 
immunoprophylaxis, alloanti-D production in given weak D 
types should be the only criterion to consider.
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